Oncology Biosimilars Market
According to Intent Market Research, the Oncology Biosimilars Market is expected to grow from USD 7.6 Billion in 2024-e at a CAGR of 14.5% to touch USD 17.2 Billion by 2030. The Oncology Biosimilars Market is dominated by key players such as Pfizer Inc., Novartis AG (Sandoz), Biocon Limited, Mylan N.V. (Viatris), Celltrion Healthcare, and Teva Pharmaceutical Industries Ltd.